<DOC>
	<DOCNO>NCT00761579</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy flexibly dose paliperidone extended-release ( ER ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>Paliperidone Extended Release ( ER ) Effectiveness Study Evaluate Objective Symptom Change Symptomatic Remission</brief_title>
	<detailed_description>This open-label , prospective ( study follow participant forward time ) , single arm , non-comparative study paliperidone Extended Release ( ER ) participant schizophrenia ( switch exist drug paliperidone ER ) . The total study duration approximately 48 week per participant . The study consist 2 part : Screening ( , 14 day study commences Day 1 ) ; Treatment ( single-oral dose paliperidone 48 week , dose range 3 12 milligram ) . Efficacy participant primarily evaluate Positive Negative Syndrome Scale . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Childbearing potential woman consent use consistently permissible contraception ( oral contraceptive , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) Participants compliant selfmedication receive consistent help support Participants need change antipsychotic drug another one follow reason among participant treat antipsychotic drug two week screen ( 1 ) Group lack efficacy : antipsychotic drug clinically require change little therapeutic response despite appropriately dose antipsychotic therapy ( 2 ) Group lack tolerance : antipsychotic drug require change due lack tolerance exist antipsychotic drug safety issue ( 3 ) Group lack compliance : antipsychotic drug require change due lack medication compliance participant want change antipsychotic drug ) Have schizophrenia diagnosis Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) Participants past history neuroleptic malignant syndrome ( NMS ) Participants suspicious clinically significant risk include suicide aggressive behavior expect unable complete study ( base investigator 's judgment ) Participants severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) participant swallow drug whole ( study drug must chew , divide , melt grind impact study drug release profile ) Participants significant abnormal finding blood chemistry , hematological urine analysis clinically significant investigator 's discretion Female Participants pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Antipsychotics Agents</keyword>
</DOC>